Cencora, Inc. (NYSE:COR) Holdings Boosted by West Family Investments Inc.

West Family Investments Inc. grew its holdings in Cencora, Inc. (NYSE:COR) by 25.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,380 shares of the company’s stock after purchasing an additional 696 shares during the period. West Family Investments Inc.’s holdings in Cencora were worth $761,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of COR. New Millennium Group LLC purchased a new stake in Cencora in the 2nd quarter worth about $26,000. TFO Wealth Partners LLC acquired a new stake in shares of Cencora during the first quarter worth approximately $30,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora during the second quarter worth approximately $30,000. Concord Wealth Partners purchased a new position in Cencora during the third quarter valued at approximately $30,000. Finally, LRI Investments LLC purchased a new stake in Cencora in the 1st quarter worth approximately $31,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 15.80% of the company’s stock.

Cencora Stock Performance

NYSE COR opened at $240.19 on Tuesday. Cencora, Inc. has a 1 year low of $194.56 and a 1 year high of $251.56. The firm has a market capitalization of $47.33 billion, a P/E ratio of 32.34, a price-to-earnings-growth ratio of 1.60 and a beta of 0.44. The firm’s fifty day moving average price is $232.62 and its two-hundred day moving average price is $231.04. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be given a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.92%. Cencora’s dividend payout ratio is currently 29.29%.

Analysts Set New Price Targets

Several brokerages recently issued reports on COR. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Evercore ISI raised their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. UBS Group boosted their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Bank of America reissued a “neutral” rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $271.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.